Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBIT (2016 - 2025)

Wave Life Sciences' EBIT history spans 11 years, with the latest figure at -$56.5 million for Q4 2025.

  • For Q4 2025, EBIT fell 345.86% year-over-year to -$56.5 million; the TTM value through Dec 2025 reached -$215.4 million, down 95.09%, while the annual FY2025 figure was -$215.4 million, 95.09% down from the prior year.
  • EBIT reached -$56.5 million in Q4 2025 per WVE's latest filing, roughly flat from -$56.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $23.0 million in Q4 2024 to a low of -$63.9 million in Q3 2024.
  • Average EBIT over 5 years is -$34.2 million, with a median of -$38.5 million recorded in 2022.
  • The largest YoY upside for EBIT was 222.94% in 2024 against a maximum downside of 1538.23% in 2024.
  • A 5-year view of EBIT shows it stood at -$36.1 million in 2021, then decreased by 20.64% to -$43.6 million in 2022, then soared by 57.11% to -$18.7 million in 2023, then soared by 222.94% to $23.0 million in 2024, then plummeted by 345.86% to -$56.5 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's EBIT are -$56.5 million (Q4 2025), -$56.4 million (Q3 2025), and -$52.8 million (Q2 2025).